BIO-WORKS TECHNOLOGIES AB
NNGM:BIOWKS3.17
SEK
+0.12
(+3.93%)
ISIN
SE0007387089
Return %
Stock
S&P 500
1Y
27.82
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Lone Carlbom
- Full Time Employees
- 31
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Virdings allé 18 Uppsala Sweden 754 50
- IPO Date
- Dec 14, 2017
- Website
- bio-works.com
- Similar Companies
- Business
- Bio-Works Technologies AB (publ) is a Swedish biotechnology company specializing in the development, manufacturing, and sale of innovative products and solutions in the bioseparation field. The company's core offerings include Protein A affinity resins, customized chromatography media, and other bioseparation technologies primarily used in biopharmaceutical manufacturing and research. Bio-Works provides products such as MabSelect SuRe, Capto, and other chromatography resins to pharmaceutical companies and research institutions globally. Its solutions facilitate the purification and production of biologics including monoclonal antibodies and vaccines. Founded in 1994 and headquartered in Uppsala, Sweden, Bio-Works Technologies operates internationally with a focus on key markets in Europe, North America, and Asia. The company serves the biopharmaceutical, life sciences, and biotech industries with high-quality bioseparation products designed to enhance process efficiency and product purity. In the past 1-2 years, Bio-Works Technologies has strategically enhanced its product portfolio with the launch of new chromatography resins and expanded its collaborative partnerships to accelerate innovation in bioprocessing. The company has also focused on consolidating its market position by investing in advanced manufacturing capabilities and expanding its global sales and distribution networks. No recent name changes or reorganizations have been reported. Bio-Works continues to strengthen its role as a trusted partner in biopharmaceutical purification technology with a comprehensive range of products and focused R&D efforts supporting next-generation biologics production.